Innovita Biological Technology Co. Ltd. A

Innovita released its 2026 interim report on August 26. During the reporting period, it achieved operating revenue of 141 million yuan, down 49.09 percent year on year. Net profit attributable to the parent company was 31.12 million yuan, down 75.12 percent. Net profit attributable to the parent company after deducting non-recurring items was 19.64 million yuan, down 82.31 percent. The decline was mainly due to weaker intensity of respiratory disease circulation and intensifying industry competition, which caused both volume and price of its main products to fall, with gross margin dropping from 78.28 percent to 71.09 percent. The company made breakthroughs in products such as a combined antigen test kit for metapneumovirus and parainfluenza virus, and obtained a registration certificate for a glial fibrillary acidic protein assay kit in the neurological testing field. However, the new business is still in the investment phase, and with rigid costs, profit pressure is evident. Net cash flow from operating activities was negative 62.38 million yuan, shifting from net inflow to net outflow.

Innovita released its 2026 half-year report. First-half operating revenue was 141 million yuan, down 49.1% year on year. Net profit attributable to the parent was 31.12 million yuan, down 75.1% year on year. Net profit attributable to the parent after deducting non-recurring items was 19.64 million yuan, down 82.3% year on year. Net operating cash flow was negative 62.38 million yuan, down 173.0% year on year. Earnings per share were 0.2271 yuan. In the second quarter, operating revenue was 31.92 million yuan, down 54.1% year on year. Net profit attributable to the parent was a loss of 9.52 million yuan, down 132.0% year on year. Net profit attributable to the parent after deducting non-recurring items was a loss of 15.61 million yuan, down 168.7% year on year. As of the end of the second quarter, total assets were 2.127 billion yuan, down 6.5% from the end of the previous year. Net assets attributable to the parent were 2.029 billion yuan, down 1.1% from the end of the previous year. The company said the decline in performance was mainly affected by changes in the intensity of respiratory disease epidemics and intensifying competition in the in vitro diagnostics market. It plans to increase investment in new products and new businesses, and has already obtained registration certificates for a combined antigen test kit for metapneumovirus and parainfluenza virus, as well as approval for a glial fibrillary acidic protein assay kit.